Autosomal Recessive Cerebellar Ataxias: Paving the Way toward Targeted Molecular Therapies
Authors:
Abstract
No abstract availableKeywords
Funding Information
- Horizon 2020 Framework Programme
- Deutsche Forschungsgemeinschaft (SCHO754/5-2)
- Bundesministerium für Forschung, Technologie und Raumfahrt (01GM1607)
- Else Kröner-Fresenius-Stiftung (2015_EKMS.018)
- Horizon 2020 (643578, 779257)
This publication has 154 references indexed in Scilit:
- Alteration of Fatty-Acid-Metabolizing Enzymes Affects Mitochondrial Form and Function in Hereditary Spastic ParaplegiaThe American Journal of Human Genetics, 2012
- Mitochondrial dysfunction and Purkinje cell loss in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)Proceedings of the National Academy of Sciences, 2012
- A TAT–Frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse modelHuman Molecular Genetics, 2011
- Aprataxin localizes to mitochondria and preserves mitochondrial functionProceedings of the National Academy of Sciences, 2011
- Ataxia telangiectasia mutated influences cytochrome c oxidase activityBiochemical and Biophysical Research Communications, 2011
- An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay–Sachs or Sandhoff variants)Molecular Genetics and Metabolism, 2011
- Role of tyrosyl-DNA phosphodiesterase (TDP1) in mitochondriaProceedings of the National Academy of Sciences, 2010
- ADCK3, an Ancestral Kinase, Is Mutated in a Form of Recessive Ataxia Associated with Coenzyme Q10 DeficiencyThe American Journal of Human Genetics, 2008
- RIDDLE immunodeficiency syndrome is linked to defects in 53BP1-mediated DNA damage signalingProceedings of the National Academy of Sciences, 2007
- Pyrimethamine as a Potential Pharmacological Chaperone for Late-onset Forms of GM2 GangliosidosisJournal of Biological Chemistry, 2007